ALNYLAM PHARMACEUTICALS, INC. Payments for (Proceeds from) Other Investing Activities
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments for (Proceeds from) Other Investing Activities of $25.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was $2.15M.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for the quarter ending 2024-12-31 was $117.00K.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for the quarter ending 2023-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for fiscal 2025 was $2.15M, a 1737.61% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for fiscal 2024 was $117.00K, a 97.36% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for fiscal 2023 was $4.44M, a 5.45% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. payments for (proceeds from) other investing activities for fiscal 2022 was $4.69M, a 11.82% increase from fiscal 2021.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 6 month as first filed | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $25.90M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $2.15M derived: sum of 2 quarters · filed 2026-02-12 | $2.15M 10-K · filed 2026-02-12 | ||
| 2025-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.15M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $117.00K 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $4.44M derived: sum of 2 quarters · filed 2026-02-12 | $4.44M derived: sum of 3 quarters · filed 2026-02-12 | $4.44M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $4.44M derived: sum of 2 quarters · filed 2024-10-31 | $4.44M 10-Q · filed 2024-10-31 | $4.06M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | -$381.00K derived: sum of 3 quarters · filed 2025-02-13 | $4.62M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | -$381.00K derived: sum of 2 quarters · filed 2025-02-13 | $4.62M derived: sum of 3 quarters · filed 2025-02-13 | $4.62M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | -$381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $4.62M derived: sum of 2 quarters · filed 2025-02-13 | $4.62M derived: sum of 3 quarters · filed 2025-02-13 | $4.69M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.00M derived: sum of 2 quarters · filed 2023-11-02 | $5.08M 10-Q · filed 2023-11-02 | $5.08M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $75.00K 10-Q · filed 2023-08-03 | $8.57M 10-Q · filed 2022-07-28 | $75.00K derived: sum of 3 quarters · filed 2024-02-15 | -$90.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $75.00K 10-Q · filed 2023-05-04 | $75.00K derived: sum of 2 quarters · filed 2024-02-15 | -$90.00K derived: sum of 3 quarters · filed 2024-02-15 | $75.00K derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$165.00K derived: sum of 2 quarters · filed 2024-02-15 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | $4.20M 10-K · filed 2024-02-15 | |
| 2021-09-30 | -$165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $4.20M 10-Q · filed 2022-10-27 | $9.20M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $4.36M 10-Q · filed 2022-07-28 | $4.20M 10-Q · filed 2021-08-03 | $9.36M derived: sum of 3 quarters · filed 2023-02-23 | $9.36M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $4.20M 10-Q · filed 2022-04-28 | $9.20M derived: sum of 2 quarters · filed 2023-02-23 | $9.20M derived: sum of 3 quarters · filed 2023-02-23 | $9.50M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $5.00M derived: sum of 2 quarters · filed 2023-02-23 | $5.30M derived: sum of 3 quarters · filed 2023-02-23 | $5.30M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $300.00K derived: sum of 2 quarters · filed 2021-10-28 | $300.00K 10-Q · filed 2021-10-28 | $7.30M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $300.00K 10-Q · filed 2021-08-03 | $7.30M derived: sum of 3 quarters · filed 2022-02-10 | $7.30M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | $7.00M derived: sum of 2 quarters · filed 2022-02-10 | $7.00M derived: sum of 3 quarters · filed 2022-02-10 | ||
| 2019-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $7.00M derived: sum of 2 quarters · filed 2022-02-10 | $7.00M 10-K · filed 2022-02-10 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |